Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2020-10-18 AGM Information
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Notice of AGM ASX Listing Rule 3.13.1 1 page 161.5K
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF AGM – ASX LISTING RULE 3.13.1' and discusses the scheduling of the Annual General Meeting (AGM) for BARD1 Life Sciences Limited. It mentions the date of the AGM, the re-election of directors as an agenda item, and instructions for nominations. The document is a notice about the AGM rather than the AGM materials or minutes themselves. It is relatively short (1928 characters) and serves as an announcement rather than a detailed report or presentation. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices related to it.
2020-10-18 English
Successful BARD1 Kit Evaluation 3 pages 159.0KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from BARD1 Life Sciences Limited about the successful optimization of a diagnostic kit for ovarian cancer. It includes scientific study results, future development plans, and background information on ovarian and breast cancer. The document is an ASX release but does not contain financial statements, regulatory certifications, or detailed financial performance data. It is primarily a corporate announcement about product development and clinical study results rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation, call transcript, or governance-related document. Given the nature of the content, it best fits into the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not neatly fit into other specific categories.
2020-09-22 English
BARD1 Awarded BTB Funding to Develop Breast Cancer Test 3 pages 191.6KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that BARD1 Life Sciences Limited has been awarded grant funding from the Biomedical Translation Bridge (BTB) program to develop breast cancer liquid biopsy tests. It details the funding amount, project goals, collaborators, and future milestones. There are no financial statements, regulatory certifications, or detailed financial performance data. The content focuses on a capital funding update related to research and development financing. It is not an annual report, earnings release, or management discussion. The document is not a report publication announcement since it contains substantive information about the funding and project. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-09-02 English
Revised Securities Trading Policy 5 pages 445.5KB
Governance Information Classification · 95% confidence The document is titled 'REVISED SECURITIES TRADING POLICY' and contains detailed policies regarding insider trading, securities trading prohibitions, and director transaction reporting requirements. It references compliance with ASX Listing Rules and the Corporations Act. The content is a policy document outlining rules and procedures for trading company securities by directors, officers, and employees. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a governance-related policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (13,829 characters) supports it being a full policy document rather than a brief announcement or notice.
2020-08-30 English
Appendix 4E and Annual Report to Shareholders 56 pages 1.5MB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final Report' and references the year ended 30 June 2020. It includes detailed financial results, directors' report, auditor's independence declaration, financial statements, notes, and an independent auditor's report. The content covers comprehensive financial performance, corporate governance, management discussion, and strategic initiatives. The presence of full financial statements and detailed management commentary indicates this is a full annual report rather than a brief announcement or a regulatory filing. The document also mentions the annual meeting and compliance statements typical of an annual report. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2020
2020-08-24 English
Appendix 4G and Corporate Governance Statement 17 pages 343.9KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures. It includes a detailed key to disclosures against the Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2020. The document is a corporate governance statement approved by the board and includes detailed disclosures about board roles, diversity policies, evaluation processes, and board structure. It is not the full annual report but a specific governance disclosure document lodged alongside the annual report as required by ASX rules. This type of document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a substantive governance report rather than a brief announcement or certification. Therefore, the correct classification is CGR with high confidence.
2020-08-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.